SouthState Corp Has $14.50 Million Position in AbbVie Inc. $ABBV

SouthState Corp increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,093 shares of the company’s stock after buying an additional 451 shares during the quarter. SouthState Corp’s holdings in AbbVie were worth $14,496,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Andra AP fonden grew its position in AbbVie by 3.3% during the second quarter. Andra AP fonden now owns 74,800 shares of the company’s stock worth $13,884,000 after buying an additional 2,400 shares in the last quarter. Horan Securities Inc. grew its position in AbbVie by 3.8% during the second quarter. Horan Securities Inc. now owns 3,989 shares of the company’s stock worth $740,000 after buying an additional 147 shares in the last quarter. Ethos Financial Group LLC boosted its holdings in shares of AbbVie by 3.4% in the 2nd quarter. Ethos Financial Group LLC now owns 11,693 shares of the company’s stock valued at $2,170,000 after purchasing an additional 387 shares in the last quarter. Stone House Investment Management LLC boosted its holdings in shares of AbbVie by 83.7% in the 2nd quarter. Stone House Investment Management LLC now owns 483 shares of the company’s stock valued at $90,000 after purchasing an additional 220 shares in the last quarter. Finally, Centerpoint Advisory Group boosted its holdings in shares of AbbVie by 5.0% in the 2nd quarter. Centerpoint Advisory Group now owns 6,340 shares of the company’s stock valued at $1,177,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price on the stock in a report on Thursday, August 7th. Morgan Stanley raised their target price on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a report on Friday, August 1st. BMO Capital Markets raised their target price on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a report on Friday, September 12th. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $238.05.

AbbVie Stock Up 0.5%

Shares of ABBV opened at $216.96 on Thursday. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $244.81. The stock has a market capitalization of $383.27 billion, a price-to-earnings ratio of 103.31, a PEG ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a fifty day moving average of $222.84 and a 200-day moving average of $201.84.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is 524.24%.

Insider Transactions at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.